Next Article in Journal
Development of a Novel Antimicrobial Screening System Targeting the Pyoverdine-Mediated Iron Acquisition System and Xenobiotic Efflux Pumps
Next Article in Special Issue
Acerogenin A from Acer nikoense Maxim Prevents Oxidative Stress-Induced Neuronal Cell Death through Nrf2-Mediated Heme Oxygenase-1 Expression in Mouse Hippocampal HT22 Cell Line
Previous Article in Journal
Special Issue: Single Molecule Techniques
Previous Article in Special Issue
Flavonoids from Sideritis Species: Human Monoamine Oxidase (hMAO) Inhibitory Activities, Molecular Docking Studies and Crystal Structure of Xanthomicrol

Riluzole as a Neuroprotective Drug for Spinal Cord Injury: From Bench to Bedside

Spinal Program, Krembil Neuroscience Center, Toronto Western Hospital, University Health Network, Toronto, ON M5T 2S8, Canada
Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan
Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan
Department of Surgery, University of Toronto, Toronto, ON M5T 1P5, Canada
Author to whom correspondence should be addressed.
Academic Editor: Peter Koulen
Molecules 2015, 20(5), 7775-7789;
Received: 3 March 2015 / Revised: 16 April 2015 / Accepted: 24 April 2015 / Published: 29 April 2015
Spinal cord injury (SCI) is a devastating event resulting in permanent loss of neurological function. To date, effective therapies for SCI have not been established. With recent progress in neurobiology, however, there is hope that drug administration could improve outcomes after SCI. Riluzole is a benzothiazole anticonvulsant with neuroprotective effects. It has been approved by the U.S. Food and Drug Administration as a safe and well-tolerated treatment for patients with amyotrophic lateral sclerosis. The mechanism of action of riluzole involves the inhibition of pathologic glutamatergic transmission in synapses of neurons via sodium channel blockade. There is convincing evidence that riluzole diminishes neurological tissue destruction and promotes functional recovery in animal SCI models. Based on these results, a phase I/IIa clinical trial with riluzole was conducted for patients with SCI between 2010 and 2011. This trial demonstrated significant improvement in neurological outcomes and showed it to be a safe drug with no serious adverse effects. Currently, an international, multi-center clinical trial (Riluzole in Acute Spinal Cord Injury Study: RISCIS) in phase II/III is in progress with riluzole for patients with SCI (, registration number NCT01597518). This article reviews the pharmacology and neuroprotective mechanisms of riluzole, and focuses on existing preclinical evidence, and emerging clinical data in the treatment of SCI. View Full-Text
Keywords: spinal cord injury; riluzole; neuroprotection; clinical trial spinal cord injury; riluzole; neuroprotection; clinical trial
Show Figures

Figure 1

MDPI and ACS Style

Nagoshi, N.; Nakashima, H.; Fehlings, M.G. Riluzole as a Neuroprotective Drug for Spinal Cord Injury: From Bench to Bedside. Molecules 2015, 20, 7775-7789.

AMA Style

Nagoshi N, Nakashima H, Fehlings MG. Riluzole as a Neuroprotective Drug for Spinal Cord Injury: From Bench to Bedside. Molecules. 2015; 20(5):7775-7789.

Chicago/Turabian Style

Nagoshi, Narihito, Hiroaki Nakashima, and Michael G. Fehlings. 2015. "Riluzole as a Neuroprotective Drug for Spinal Cord Injury: From Bench to Bedside" Molecules 20, no. 5: 7775-7789.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop